PCI The Journeys Within
Media Pack
News

Current Edition

JCS - Volume 18 Issue 3 - Autumn 2026
Frankfurt 2027 – 12/10/26
ramusmedical
Regional News

Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO

Argenx is off to the races with the launch of its new med Vyvgart. With its first FDA-approved drug Vyvgart now rolling out, Argenx is charting a course to become an...
26 January 2022 Regional News Argenx | CEO
Continue Reading →
Regional News

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with t...
26 October 2021 Regional News Dupixent | immunology
Continue Reading →
news

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data...
15 November 2017 news cancer | clinical
Continue Reading →
Quotient
jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte